Is TNGX a good stock to buy?We came across a bullish thesis on Tango Therapeutics, Inc. on BioEquity Watch's Substack. Since the thesis was published on August 28th, TNGX shares have edged lower as investors weighed updated trial results against the stronger initial data, creating a near-term sentiment headwind while the promising results and planned Phase 3 trial keep the longer-term opportunity in view. In this article, we will summarize the bulls' thesis on TNGX. Tango Therapeutics, Inc.'s share was trading at $22.89 as of October 27th 2026.
This isn't the first time we see a biotechnology company pitched as a great investment. TNGX shares gained 192.34% over the last 12 months. Comparable stocks like Relay Therapeutics and Nurix Therapeutics gained 157.73% and 128.21%, respectively, during the same period. Why are biotechnology stocks rising so much and is it really a good time to buy them?
Likoper/Shutterstock.com
In June, we published an article about the 10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds and TNGX ranked #9 in that article. TNGX returned 13.20% since then. So, hedge funds were right about TNGX. This article explains why Stifel, an investment banking and wealth management firm, remains bullish on Tango Therapeutics. Before getting into our analysis, let's take a look at the business and why some investors like the stock so much.
Tango Therapeutics, Inc. (NASDAQ:TNGX) is a clinical-stage biotech company working on cancer treatments using a method called synthetic lethality. The investment case centers on its lead drug, vopimetostat, and the belief that investors are too focused on the severe bone-marrow side effects that hurt earlier, similar drugs from competitors. Early human data suggest vopimetostat may avoid that problem while still fighting tumors effectively, especially in pancreatic cancer and in combination with other treatments.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Tango currently has almost no revenue, since its research partnership with Gilead ended in 2025, and it lost $100.9 million in the first half of 2026. The stock trades at $25.33, but the valuation used here comes out to $47.92 per share, roughly 89% higher. That gap is essentially a bet that larger clinical trials will confirm the encouraging early results.
The optimistic case is built around a genetic flaw called MTAP deletion, found in about 10% to 15% of all human cancers. This flaw makes tumor cells reliant on a specific pathway, and vopimetostat is designed to block that pathway while leaving healthy cells alone. In an advanced pancreatic cancer study, the drug kept the disease from worsening for roughly seven months and shrank tumors in about a quarter of patients ( see how much of Tango's striking pancreatic-cancer data may already be priced in ).
In another hard-to-treat cancer group, it delayed progression for about nine months and helped roughly half of patients respond to treatment. Results improved further when vopimetostat was combined with drugs from Revolution Medicines, including one pancreatic cancer group where the vast majority of patients saw their tumors shrink, without the severe blood-related side effects seen with older drugs.
Tango is currently using a 250 mg daily dose and plans to start a larger, roughly 300-patient pancreatic cancer trial in the fourth quarter of 2026. More data are expected on a similar timeline: combination results with Revolution Medicines in the second half of 2026, brain-related safety data for a separate drug, TNG456, in the first half of 2027, and an update on a lung cancer program around mid-2027.
Beyond vopimetostat, TNG456 is being developed for brain tumors, and another drug, TNG260, aims to make certain lung cancers more responsive to the immune system. Patents on vopimetostat run into the late 2030s, and some of Tango's programs also carry orphan-drug status, which grants seven years of exclusivity after approval — giving Tango a head start before competitors can catch up.
Since Tango has no product revenue yet, its $47.92 price target comes from estimating the value of its future cash flows rather than current sales. After adding the company's roughly $1 billion in net cash to that estimate, the total fair value works out to about $1.92 billion, or $47.92 per share based on the number of shares outstanding — about 89% above where the stock trades today. This target depends heavily on vopimetostat continuing to succeed in trials and eventually reaching the market. If the drug performs well enough, it could also end up being used earlier in a patient's treatment rather than as a last resort.
The biggest risk is that vopimetostat's strong early results don't hold up once tested on a larger, more varied group of patients. If the upcoming pancreatic cancer trial shows weaker response rates or fails to clearly beat chemotherapy, much of the projected value would disappear. Unexpected side effects from combination treatments could also slow development or invite closer regulatory scrutiny. Tango still has about $1 billion in cash after raising funds earlier this year, which should be enough to fund its key programs for several years. It spent $37.2 million on research and development and $22.6 million on general expenses in the first half of 2026. If a trial fails or needs to be redone, cash burn would likely accelerate, forcing Tango to raise more money. In that worst-case scenario, the stock could fall to somewhere between $8 and $10, closer to the value of its cash alone.
Another risk for the stock is the difficulty of identifying enough patients eligible for its targeted treatments. Vopimetostat's opportunity depends on finding tumors with MTAP deletion, rather than treating cancer patients broadly. Tango relies on third-party biomarker testing and warns that delays in developing or validating diagnostic tests can limit its programs' commercial potential. If testing is unavailable or not routinely used, eligible patients could remain unidentified. This could slow trial enrollment and, if the drug is approved, limit treatment uptake. Strong clinical results would not automatically translate into the sales assumed in the valuation. In our opinion, the projected upside becomes harder to justify if diagnostic access prevents Tango from reaching enough suitable patients.
Hedge fund positioning shows a strong signal. As per our database, 66 hedge funds held shares of Tango Therapeutics, Inc. by the end of the second quarter, sharply up from 48 in the prior quarter. This fast increase suggests institutional investors have grown more confident in vopimetostat's progress and Tango's cash position, even with the risks that come from larger trials still ahead. In comparison, Nurix Therapeutics, Inc. (NASDAQ:NRIX) was held by 41 hedge funds, unchanged from the prior quarter, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) was held by 42 hedge funds, up from 36, and Relay Therapeutics, Inc. (NASDAQ:RLAY) was held by 42 hedge funds, up from 40. Tango Therapeutics, Inc. stood out with by far the largest jump in hedge fund interest among the group.
Short interest data also paints a fairly cautious picture for Tango Therapeutics, Inc. relative to its peers. About 26.69% of Tango Therapeutics, Inc.'s float is sold short, above Relay Therapeutics, Inc. at 24.84% and well above Nurix Therapeutics, Inc. at 16.33% and IDEAYA Biosciences, Inc. at 11.05%. This suggests Tango Therapeutics, Inc. is drawing the most skepticism among the four companies, even as its stronger hedge fund buying points to a sharp divide in investor expectations.
Valuation Analysis
TNGX's P/B is 3.65x. Nurix Therapeutics, Inc., IDEAYA Biosciences, Inc., and Relay Therapeutics, Inc. trade at P/B multiples of 2.88x, 2.64x, and 4.47x, respectively. We believe the current valuation reflects expectations for vopimetostat's clinical potential, balanced against uncertainty about larger trials and future funding needs. However, its discount to Relay does not establish undervaluation, since Tango trades above Nurix and IDEAYA and each company has different clinical prospects. Tango reported a $100.9 million net loss in the first half of 2026 and held roughly $1 billion in cash, providing development funding while underscoring that its value depends on future trial results rather than current earnings. We believe TNGX can justify its premium to book value if larger studies confirm vopimetostat's efficacy and safety before research spending substantially reduces its cash reserves. If Tango delivers that evidence and manages its funding carefully, the current valuation could offer an attractive entry point despite the risks surrounding clinical development and eventual approval.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy's commercialization, cash position, and gene-editing pipeline. CRSP's stock price has appreciated by approximately 25.82% since our coverage.We believe TNGX could offer an attractive entry point if larger trials confirm vopimetostat's safety and efficacy, but its upside depends on clinical success and access to diagnostic testing.
Tango Therapeutics, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds . While TNGX could offer long-term upside if larger trials confirm vopimetostat's efficacy and safety, we believe certain AI infrastructure stocks offer far stronger long-term potential at a much more attractive entry point. If you are looking for an AI stock more promising than ACN that operates as a critical AI tollboothand stands as the most important company in the world, check out our report about this must-own AI stock .
Disclosure: None.
